NerveGen Pharma’s Game-Changer: NVG-291’s SCI Trial Results Soon part 1

About this Video

• Video Title: NerveGen Pharma’s Game-Changer: NVG-291’s SCI Trial Results Soon part 1
• Channel: Clay Jay
• Speakers: Mike Kelly (President and CEO of NerveGen Pharma), Clay Jay (Interviewer)
• Duration: 00:14:58

Introduction

This video features an interview with Mike Kelly, President and CEO of NerveGen Pharma, discussing the company's work on neuro-reparative therapies, specifically focusing on NVG-291 for spinal cord injury (SCI). The main purpose is to provide an overview of NerveGen Pharma, its lead molecule NVG-291, and the upcoming phase 1b/2a trial results for SCI.

Key Takeaways

• NerveGen Pharma is a clinical-stage biotech company developing neuro-reparative therapies for conditions like spinal cord injury and ALS.
• NVG-291 is a lead molecule designed to inhibit inhibitors of nerve regeneration, specifically targeting CSPGs (chondroitin sulfate proteoglycans) involved in scar tissue formation after spinal cord injury.
• A phase 1b/2a clinical trial for NVG-291 in SCI is underway, with primary endpoints focusing on measuring improved nerve connectivity and secondary endpoints assessing functional improvements (e.g., walking, grip strength).
• The SCI market presents a significant multi-billion dollar opportunity, as there are currently no effective treatments to regenerate nerves after injury.
• Data from the phase 1b/2a trial is expected in Q2 (May/June), paving the way for potential phase 3 trials.